EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure

TY - JOUR

T1 - EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure

AU - Rezvani, K.

AU - Kanfer, E. J.

AU - Marin, D.

AU - Gabriel, I.

AU - Rahemtulla, A.

AU - Taylor, A.

AU - Macdonald, D.

AU - Dazzi, F.

AU - Milojkovic, D.

AU - Foroni, L.

AU - Pavlu, J.

AU - Sargent, J.

AU - Le Dieu, R.

AU - Goldman, J. M.

AU - Apperley, J.

AU - Szydlo, R.

PY - 2012/2

Y1 - 2012/2

N2 - Increasing numbers of allogeneic hematopoietic stem cell transplantation (allo-SCT) are being performed for patients who have failed a previous allogeneic or autologous SCT. We investigated whether the EBMT risk score could predict outcome after a subsequent allo-SCT. We analyzed prognostic factors in 124 consecutive patients who underwent a second transplantation using an allogeneic donor at our institution. Patients with either a first autologous (N = 64) or first allogeneic (N = 60) SCT were included. Age, disease stage, time interval from diagnosis to transplantation, donor type, and donor-recipient sex combination were used to establish a score from 0 to 7 points, from which 3 groups were identified. The 5-year survival probability decreased from 51.7% for risk scores 0-3 (low, n = 25), to 29.3% for risk score 4 (intermediate, n = 42), and only 10.4% for risk scores 5-7 (high, n = 57), P = .001. We propose that the EBMT risk score can identify patients most likely to benefit from a second transplantation.

AB - Increasing numbers of allogeneic hematopoietic stem cell transplantation (allo-SCT) are being performed for patients who have failed a previous allogeneic or autologous SCT. We investigated whether the EBMT risk score could predict outcome after a subsequent allo-SCT. We analyzed prognostic factors in 124 consecutive patients who underwent a second transplantation using an allogeneic donor at our institution. Patients with either a first autologous (N = 64) or first allogeneic (N = 60) SCT were included. Age, disease stage, time interval from diagnosis to transplantation, donor type, and donor-recipient sex combination were used to establish a score from 0 to 7 points, from which 3 groups were identified. The 5-year survival probability decreased from 51.7% for risk scores 0-3 (low, n = 25), to 29.3% for risk score 4 (intermediate, n = 42), and only 10.4% for risk scores 5-7 (high, n = 57), P = .001. We propose that the EBMT risk score can identify patients most likely to benefit from a second transplantation.

KW - Adolescent Adult Age Factors Child Disease-Free Survival Female Hematologic Neoplasms/mortality/therapy Hematopoietic Stem Cell Transplantation Humans Male Middle Aged Retrospective Studies Risk Factors Sex Factors Survival Rate Transplantation, Autologou

U2 - 10.1016/j.bbmt.2011.06.010

DO - 10.1016/j.bbmt.2011.06.010

M3 - Article

SN - 1083-8791

VL - 18

SP - 235

EP - 240

JO - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

JF - BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

IS - 2

M1 - N/A

ER -